|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The intensity of SSTR5 expression and the granulation pattern of adenomas were of limited value for the prediction of Pasireotide-LAR effectiveness.
|
31518993 |
2019 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RESULTS IHC of SSTR subtypes in the different cohorts showed SSTR2 staining intensity scores higher than SSTR5 in TSHoma, acromegaly and prolactinoma, whereas the expression of SSTR5 was stronger than SSTR2 in corticotropinoma and NFPA.
|
28434012 |
2017 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings demonstrated that TSH-secreting adenomas express sstr1, 2A, 3 and 5 mRNAs, predominantly sstr2A, and in addition to the expression of sstr2 mRNA, the expression level of sstr5 mRNA may be a factor affecting the tumor shrinkage by somatostatin analogues against TSH-secreting adenomas.
|
17420609 |
2007 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.
|
15994755 |
2005 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No correlation between SSTR2 and SSTR5 genotypes, responsiveness to somatostatin therapy, and mRNA expression in the removed adenomas (n = 10) was found.
|
15914528 |
2005 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the SSTR5-preferring analog showed a slight additive effect when used in combination with SSTR2 preferential drugs at submaximal concentrations in octreotide partially sensitive adenomas.
|
11231991 |
2001 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We quantified the expression of SSTR2 and SSTR5 mRNA using a semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) in 19 human growth hormone (GH) -secreting adenomas.
|
11264647 |
2001 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, studies using somatostatin (SRIF) analogs preferential for either the SRIF receptor 2 (SSTR2) or the SSTR5 subtype demonstrated a variable suppression of GH and PRL release from GH-secreting human adenomas.
|
10690891 |
2000 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Six of 9 somatotroph adenomas, 1 of 4 lactotroph adenomas and 1 of 2 thyrotroph adenomas also expressed SSTR5.
|
8866248 |
1996 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, SSTR5 was highly expressed in 10 of 11 GH-secreting adenomas and 1 prolactinoma.
|
7521350 |
1994 |